Growth Prospects in the USA Sleep Apnea Devices Market

 In the United States, the prevalence of sleep apnea is estimated to be around 18% of the adult population.

The number of people with sleep apnea is expected to increase due to the aging population and the rising prevalence of obesity. The Centers for Disease Control and Prevention (CDC) estimates that sleep apnea affects over 22 million adults in the United States.

The government of the United States has launched several initiatives to promote the use of sleep apnea devices, such as subsidies for the purchase of devices and awareness campaigns. The CDC has also launched a campaign called "Stop the Snore, Save Your Life" to raise awareness about sleep apnea and its risks.

Factors Driving the Growth of Sleep Apnea Devices Market in the United States:

# Increasing prevalence of sleep apnea
# Rising awareness about sleep apnea
# Government initiatives to promote the use of sleep apnea devices
# Growing adoption of home-based sleep apnea treatment
# Increasing number of distributors and retailers selling sleep apnea devices

Factors Which May Hinder the Growth:

# High cost of sleep apnea devices
# Lack of awareness about sleep apnea
# Inadequate reimbursement for sleep apnea devices
# Side effects of sleep apnea devices

The sleep apnea devices market in the United States is segmented by type, end-user, and distribution channel.

By type, the market is segmented into continuous positive airway pressure (CPAP) devices, oral appliances, and other devices. CPAP devices are the most commonly used type of sleep apnea devices. Oral appliances are less effective than CPAP devices, but they are more comfortable to use. Other devices include bilevel positive airway pressure (BiPAP) devices and adjustable pressure ventilation (APV) devices.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=719

By end-user, the market is segmented into hospitals, clinics, and homecare settings. Hospitals are the largest end-user segment of the market. Clinics and homecare settings are expected to grow at a faster pace than hospitals due to the increasing adoption of home-based sleep apnea treatment.

By distribution channel, the market is segmented into direct sales and indirect sales. Direct sales are the largest distribution channel of the market. Indirect sales are expected to grow at a faster pace than direct sales due to the increasing number of distributors and retailers selling sleep apnea devices.

The key players in the sleep apnea devices market in the United States include ResMed, Philips Healthcare, Fisher & Paykel Healthcare, and SomnoMed. These players are focusing on expanding their product portfolio, investing in research and development, and acquiring smaller players to strengthen their market position.

You Can Also Read the Global Report on Sleep Apnea Devices Market, Here@
https://www.marketsandmarkets.com/Market-Reports/sleep-apnea-devices-market-719.html

Latin American Flow Cytometry Market - This is How Leading Companies are Dominating Global Market

Global Growth Driving Factors:

Factors such as growing prevalence of cancer and HIV/ AIDS, growing adoption of flow cytometry techniques in research activities, and increasing number of technological advancements in the flow cytometry instruments and software are prominently driving the market growth. However, the high cost of flow cytometry products such as instruments and consumables is the major factor expected to restrain market growth to a certain extent.

Global Leading Companies:

The Latin American flow cytometry market is highly consolidated. Prominent market players include Becton, Dickinson and Company (US), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Bio-Rad Laboratories Inc. (US), Miltenyi Biotec GmbH (Germany), Luminex Corporation (US).

Growth Strategies Adopted:

These companies offer a wide range of flow cytometry products as well as services focusing on innovating. However, the high market consolidation acts as a barrier for new entrants in the market.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=179088054

Recent Developments:

# In August 2022, BD (US) collaborated with Laboratory Corporation of America Holdings (Labcorp) (US) to develop flow cytometry-based companion diagnostics (CDx) for treatments against cancer and other diseases.

# In March 2021, Danaher Corporation (US) launched the CytoFLEX SRT Benchtop Cell Sorter, which is built on the principles of CytoFLEX to make multicolor applications accessible.

More About Leading Players:

Becton, Dickinson and Company (US) is the leading player in the Latin American flow cytometry market. The company has a comprehensive flow cytometry product portfolio. BD focuses on innovating technologically and has been launching products consistently. For instance, the company launched the FACSymphony A5 SE Cell Analyzer. This fluorescence-activated and spectral-enabled cell analyzer allows researchers to choose between spectral or compensation-based cell analysis to meet different flow cytometry needs.

The company dominates the flow cytometry market in Latin America due to factors such as the high reliability of diagnostic centres and other end user on BD products and the company’s strong image as a brand. Besides, the company maintains a strong geographic presence in Latin American countries through a wide and well-established network of distributors. The company is highly focused on consistency in the quality of its products & services and efficient adaptation in new business environments.

Danaher Corporation (US) is one of the leading players in the flow cytometry market in Latin America. Danaher offers products & services for medical, industrial and commercial applications through Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions business segments. The company is focused on growing through developments such as product launches and acquisitions. In June 2011, Danaher (US) acquired Beckman Coulter, Inc.

The company offers flow cytometry products through Beckman Coulter, Inc. Beckman Coulter adds to Danaher’s revenue growth through innovative research, advancement, expansion, and the launch of novel flow cytometry products. Between 2019 and 2021, Beckman Coulter registered many acquisitions and product launches in the flow cytometry market. This has led to the company establishing a strong position in the global as well as the Latin American Market.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=179088054

Geographical Growth Dynamics:

Brazil is the largest country-level market and Mexico was the fastest-growing country of the Latin American Flow Cytometry market in 2021.

On the basis of country, the flow cytometry market in Latin America is segmented into Brazil, Mexico, Argentina, Colombia, Chile, and the Rest of Latin America. Brazil accounted for the largest share of the Latin American flow cytometry market. Factors such as the growing emphasis on cancer research, the development of effective treatments, and support for the improvement of scientific research in the country contribute to the large share of Brazil in the Latin American flow cytometry market.

Clinical Trial Supplies Market - Emerging Trends & Global Future Forecasts

Global Growth Drivers:

Factors such as growing R&D expenditure in biopharmaceutical and pharmaceutical companies and the growing number of clinical trials conducted globally. However, during the forecast period, the growing cost of clinical trials and drug development is expected to restrain the growth of this market.

Projected Surge in Revenue Generation:

The global clinical trial supplies market in terms of revenue was estimated to be worth $3.6 billion in 2022 and is poised to reach $5.7 billion by 2027, growing at a CAGR of 9.7% from 2022 to 2027.

Recent Developments:

# In February 2022, Thermo Fisher entered into a partnership with Medidata to optimize clinical research site selection and speed up patient enrollment in clinical trials.

# In April 2021, Catalent added cryogenic capabilities at its Philadelphia clinical supply services facility. This expansion helped increase Catalent’s capabilities in gene therapies, packaging, labeling, and distribution of cryogenic materials for clinical trials.

# In April 2021, Parexel collaborated with Veeva Systems to improve their clinical processes for clinical trial delivery and enhance Veeva’s cloud technology.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=172240059

The logistics and distribution segment accounted for the largest share of the services segment in the clinical trial supplies market in 2021.

On the basis of the service, the clinical trial supplies market is segmented into manufacturing; packaging, labeling, and blinding; comparator sourcing; logistics & distribution; storage & retention; and other services. In 2021, Logistics & distribution services accounted for a share in the market. During the forecast period, this segment is estimated to grow at the highest CAGR. Logistics & distribution and storage & retention are seen to be the leading segments with respect to the growth rate during the forecast period as a result of growing decentralization of clinical trials.

The oncology segment accounted for the largest share of the therapeutic area segment in the clinical trial supplies market in 2021

On the basis of therapeutic area, the clinical trial supplies market is divided into oncology, CNS & mental disorders, cardiovascular diseases, digestive disorders, infectious diseases, metabolic disorders, immunology, blood disorders, and other therapeutic areas (respiratory disorders, dermatological disorders, rare diseases, ENT diseases, Nephrology). In 2021, Oncology accounted for the largest segment in this market. Factors such as increasing number of research studies on cancer therapeutics and the growing companies focusing on cancer drugs into the market. During the forecast period, the oncology segment is projected to grow at the highest CAGR.

The Asia Pacific region is the fastest-growing region of the clinical trial supplies market in 2021.

On the basis of region, the clinical trial supplies market is broadly segmented into North America, Europe, the Asia Pacific, and the Rest of the World. During the forecast period, the Asia Pacific market is projected to register the highest growth. Factors such as emerging number of players, regulatory framework, huge population base and cost-effectiveness in Asia Pacific regions is driving the growth in the market. This is attracting the attention of a majority of pharmaceutical, biopharmaceutical, and biotechnology giants to consider conducting their clinical trials in Asia Pacific countries.

Global Key Players:

Key players in the Clinical trial supplies market include Thermo Fisher Scientific (US), Marken (US), Catalent, Inc. (US), Eurofins Scientific (France), and PRA Health Sciences (US).

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=172240059

Fill Finish Manufacturing Market - Leading Companies & Their Global Dominance

Drivers: Rising technological advancements in fill-finish manufacturing processes

Technological advancements in aseptic fill-finish operations involve the usage of isolators and restricted-access barrier systems (RABS), which create robust sterile manufacturing environments that effectively separate human operators from the fill-finish process. Many equipment manufacturers in the fill finish manufacturing market are focusing on the development of barrier isolation systems, which are integrated fill-finish machines capable of carrying out all stages of fill-finish processes.

In contrast to barrier isolation systems, standalone equipment used in fill-finish operations is both time-consuming and expensive, thus making the entire process complex and prone to contamination. The SA25 aseptic filling workcell by Vanrx Pharma is an example of an isolated system. Owing to the benefits of isolators or RABS, many biopharmaceutical companies are adopting these machines in drug production facilities.

Restraints: High costs associated with isolators and RABs

RABS and isolators have advanced features and functionalities. The equipment provides an enclosed environment, which reduces the risk of contamination. RABS and isolators are expensive as compared to standalone systems. The average price of RABS and isolators is around USD 4.0 million to USD 8.0 million, which is high for standalone systems.

This severely limits the accessibility of small businesses. In underdeveloped or developing countries, the adoption of isolators and RABS is very low as compared to standalone systems. Standalone systems are still used in small pharmaceutical and biopharmaceutical companies, R&D laboratories, and academic institutes.

Download PDF Brochure for More Details@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=6249609

Global Leading Companies:

The major players in the global fill-finish manufacturing market include Syntegon Technology GmbH (Germany), I.M.A. (Industria Macchine Automatiche) S.p.A. (Italy), Becton, Dickson and Company (US), Stevanato Group (Italy), West Pharmaceutical Services, Inc. (US), OPTIMA Packaging Group GmbH (Germany), Bausch+Strobel (Germany), Groninger & Co. GmbH (Germany), and Gerresheimer AG (Germany).

Growth Strategies Adopted by Leading Players:

These players have adopted various growth strategies such as product launches, acquisitions, agreements, and partnerships to increase their presence in the global fill-finish manufacturing industry.

Recent Developments:

# In 2022, BD entered into an agreement with Mitsubishi Gas Chemical Company to investigate the further development of OXYCAPT, an innovation from MGC that integrates the best of plastic and glass for plastic syringes.

# In 2021, West Pharmaceutical introduced the DeltaCube Modeling Platform and NovaGuard SA Pro Safety System for 0.5 mL standard glass syringes at Interphex.

Syntegon Technology GmbH (Germany) is a leading player in the global fill-finish manufacturing market. The company focuses on product innovation to strengthen its position in the market. The company offers an broad product portfolio in the market through its machinery systems segment, which includes a wide range of automated standalone machines, integrated systems, and barrier systems such as isolator systems and RABS.

I.M.A. (Industria Macchine Automatiche) S.p.A. (Italy) is a leading player in the global fill-finish manufacturing market. IMA is one of the leading manufacturers of automated machines for the processing and packaging of pharmaceuticals, cosmetics, tea, food, and coffee. The company operates through three business segments—Pharmaceutical; Tobacco Packaging; Tea, Food, & Others. Through its Pharmaceutical segment, IMA deals with the production of machines for processing and packaging of capsules; filling liquid and powdered products in bottles and vials; and tube filling and other pharmaceutical operations. In 2021, BC partners have acquired IMA group and now working under them.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=6249609

Geographical Growth Scenario:

Europe accounted for the largest share of the fill-finish manufacturing market.

Europe accounted for the largest share of the market among all the regions. Factors such as well-established reimbursement systems for drugs have further enhanced the demand for biologics among patients by making them affordable to consume, and to fulfill this, biopharmaceutical companies have increased their production volumes and expand production capacities and increasing focus on the development of biosimilar due to the patent expiry of key biologics products.

Cell Isolation Market - Different Growth Strategies Adopted by Leading Companies

Overview of This Study:

This study involved four major activities in estimating the current size of the cell isolation market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Major Growth Driving Factors:

Growth in this market is largely driven by factors such as the increasing government funding for cell-based research, the increasing number of patients suffering from cancer and infectious diseases, technological advancements, and the growing focus on personalized medicine. On the other hand, ethical issues related to embryonic stem cell isolation and the high cost of cell-based research are expected to limit market growth to a certain extent in the coming years.

Find More Details – Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=103931479

Global Leading Companies:

The major players in this market are Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company Limited (US), Beckman Coulter Inc. (US).Merck KGaA (Germany), Terumo BCT (Japan), GE Healthcare (US), Bio- Rad Laboratories Inc. (US), Corning Inc. (US), Roche Diagnostics (Switzerland, Alfa Laval (Sweden), Miltenyl Biotech (Germany), pluriSelect Life Science (Germany), STEMCELL Technologies Inc. (Canada), Akadeum Life Sciences, Inc (US), Bio- Techne (US), Bio Legend (US) and Invent Biotechnologies (US).

Thermo Fisher Scientific accounted for the largest share of the cell isolation market in 2019. The company offers an exhaustive product portfolio comprising various cell isolation products, such as reagents and kits, media, magnetic beads, and centrifuges. The company pursues both organic as well as inorganic growth strategies to enhance its market position. To maintain its leading position and enhance its market share, the company is customer-oriented and maintains a strong relationship with its customers.

In 2019, Becton, Dickinson and Company accounted for the second-largest share of the cell isolation market. It operates in the cell isolation market through its BD Biosciences segment.The company has an extensive product portfolio, ranging from instruments to accessories. It also has a strong distribution network for flow cytometers, reagents, kits, and magnetic separators. The company has been focusing on technological advancements as its key growth strategy, to maintain its position in the market.

Beckman Coulter, Inc. was the third-largest player in the cell isolation market, in 2019. To sustain its leadership position in the market, the company focuses on continuous innovation and product development. For instance, the company launched its ClearLLab 10C System for the clinical flow cytometry lab in 2019. The new system includes the first 10-color CE-IVD panels of immunophenotyping reagents for both lymphoid and myeloid lineages.

Recent Developments by Leading Companies:

# In May 2019, Thermo Fisher Scientific acquired Brammer Bio with the aim to expand capabilities to support the high growth gene and cell therapy market.

# In October 2018, Merck opened its M Lab Collaboration Center in Sao Paulo

# In May 2019, Beckman Coulter launched ClearLLab 10C System

Request to Get the Customized Information@
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=103931479

Geographical Growth Scenario:

North America is the largest regional market for cell isolation market

The cell isolation market is segmented into four regions, namely, North America, Europe, Asia Pacific and Rest of the world. In 2019, North America accounted for the largest share of the cell isolation market. The large share of North America can be attributed to technological advancements, growth in the biotechnology and pharmaceutical industries, increasing prevalence of chronic and infectious diseases, and higher investments in cell-based research in the region.

Veterinary PoC Diagnostics Industry - Major Leaders & Their Dominance in the Global Industry

Overview of This Study:

The study involved four major activities in estimating the size of the global veterinary point-of-care diagnostics market. Exhaustive secondary research was done to collect information on the adoption of different technologies and their regional adoption trends. Industry experts further validated the data obtained through secondary research through primary research.

Furthermore, the market size estimates and forecast provided in this study are derived through a mix of the bottom-up approach (country-level incidence data for various diseases) and top-down approach (assessment of utilization/adoption/penetration trends, by product, technology, application, animal type, and end user). After that, market breakdown and data triangulation methods were used to estimate the market size of segments and subsegments.

Major Growth Driving Factors:

Factors such as increasing prevalence of zoonotic diseases among companion and livestock animals and the growing need for the rapid detection of these diseases, along with the advantages of POCT over laboratory analysis are driving the growth of this market during the forecast period. However, the high cost of veterinary imaging instruments is restraining the growth of this market to some extent.

Find More Details - Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105329994

Global Leading Companies:

Some of the other prominent players operating in the veterinary point-of-care diagnostics market are Heska Corporation (US), Virbac (France), Thermo Fisher Scientific, Inc. (US), Eurolyser Diagnostica GmbH (Austria), Woodley Equipment Company (UK), Randox Laboratories LTD. (UK), AniPOC, Ltd. (UK), Carestream Health, Inc. (a part of ONEX Corporation) (Canada), NeuroLogica Corporation (a part of Samsung Electronics Co. Ltd.) (South Korea), and FUJIFILM SonoSite (a part of FUJIFILM Holdings Corporation) (Japan).

Zoetis, Inc. (US) dominated the global veterinary point-of-care diagnostics market 2018. The company has a diversified product portfolio, which includes a wide range of point-of-care diagnostic products. IDEXX’s position in the market is attributed to its active R&D activities and wide distribution footprint across the world. To garner a larger share of the market, the company continuously focuses on product developments and launches.

IDEXX Laboratories, Inc. (US) accounted for the second-largest share of the veterinary point-of-care diagnostics market in 2018. Its dominance in the market can be attributed to its wide range of product offerings and its strong geographical footprint. In 2018, the company acquired Abaxis, Inc. (US), a pioneer in the veterinary point-of-care diagnostics industry for USD 2.0 billion. The company also focuses on R&D activities to develop its animal health solutions that meet the customers’ demands.

Recent Developments by Leading Companies:

# In 2019, IDEXX Laboratories launched a Canine Progesterone Test for Catalyst Dx and Catalyst One Chemistry Analyzers.

# In 2019, Zoetis, Inc. launched Stablelab, a handheld point-of-care diagnostic blood test for equine.

# In 2019, FUJIFILM SonoSite partnered with Partners Healthcare (US) to enable clinicians to perform scans at point of care.

# In 2019, Eurolyser partnered with Sysmex Corporation (Japan) to sell Eurolyser’s point of care systems measuring CRP.

Request to Get the Customized Information@
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=105329994

Geographical Growth Scenario:

North America will continue to dominate the market during the forecast period

The market, by region, is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the veterinary point-of-care diagnostics market in 2018. The large share of North America in the global market can be attributed to the increasing adoption of companion animals, growing veterinary healthcare expenditure, and rising demand for animal-derived food products.

Electrosurgery Market - Dominance of Global Leading Companies

Recent Developments:

# In April 2022, Ethicon, Inc. (US) (J&J) launched an electrosurgical generator for use in a wide variety of open and laparoscopic procedures. It is a microprocessor-controlled, isolated output, high-frequency generator with the ability to facilitate both monopolar cutting and coagulation as well as bipolar coagulation through an accessory electrode.

# In May 2022, collaboration between Medtronic (Ireland) and DaVita Inc. (US) aimed at the formation of a new, independent kidney care-focused medical device company ("NewCo" or "the Company") to enhance patient treatment experience and improve overall outcomes.

Global Leading Companies:

Prominent players in this market include Medtronic plc (Ireland), Ethicon, Inc. (a subsidiary of Johnson & Johnson, US), Olympus Corporation (Japan), B. Braun Melsungen AG (Germany), CONMED Corporation (US), Boston Scientific (US), Smith and Nephew Plc (UK), Erbe Elektromedizin GmbH (Germany), KLS Martin (Germany), BOWA-electronic GmbH & Co. KG (Germany), The Cooper Companies, Inc. (US), Kirwan Surgical Products LLC (US), Zimmer Biomet Holdings, Inc. (US), Utah Medical Products Inc. (US), Encision Inc. (US), Stryker Corporation (US), Meyer-Haake GmbH Medical Innovations (Germany), Surgical Innovations (UK), I. C. Medical, Inc. (US), Symmetry Surgical Inc. (US), and Applied Medical Resources Corporation (US).

Projected Revenue Surge:

The electrosurgery market is projected to reach USD 8.3 billion by 2027 from USD 6.2 billion in 2022 at a CAGR of 6.0% during the forecast period.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142006761

Major Growth Driving Factors:

The growth of this market is mainly driven by factors such as the growing prevalence of chronic diseases, increasing demand for minimally invasive procedures, innovation and technological advancements in electrosurgical instruments, increasing number of hospitals (coupled with the increasing number of surgical procedures), and the shifting preference toward outpatient surgeries in developed regions.

Medtronic, plc.

Medtronic is the leading player in this market. The company offers a wide range of products in the field of electrosurgery. Medtronic strategically invests in R&D to strengthen its position in the market. It invested USD 2,493 million, USD 2,331 million, and USD 2,330 million in R&D in 2021, 2020, and 2019, respectively. The company’s strong investments in developing innovative products have helped it to become a reputed player in the electrosurgery market.

Johnson & Johnson (ethicon).

Johnson & Johnson (Ethicon) accounted for the second-largest share of the electrosurgery market in 2021. Johnson & Johnson has a strong brand value among electrosurgery instrument end users and strong R&D capabilities. The company is constantly increasing its investments in R&D to accelerate innovative product development activities. In FY 2021, the company invested USD 14.7 billion in R&D, out of which USD 2.4 billion was invested in its Medical Devices business segment (an increase of 21% compared to FY 2020). These investments are aimed at discovering, testing, and developing new products and improving existing products.

Olympus Corporation.

Olympus Corporation accounted for the third-largest share of the electrosurgery market in 2021. Olympus Corporation is a leading player in the electrosurgery market with a strong leadership mindset and influential vision. The company constantly strives to upgrade its product and technology portfolios with technology upgrades. With its strong geographic presence and wide distribution network, the company has established itself as a leader in the global market. The company significantly invests in R&D activities to add technologically innovative solutions to its portfolio, which helps it to further strengthen its presence in the electrosurgery market.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=142006761